AbbVie highlights dermatology research at 2026 EADV Congress
AbbVie disclosed new clinical and real-world evidence across multiple immune-mediated skin diseases at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, with data on drugs like risankizumab and upadacitinib and early-stage studies on investigational compounds. The company says the research spans diverse patient groups and aims to inform treatment choices in dermatology.
What the new data show
AbbVie announced new abstracts and presentations from its dermatology portfolio at the EADV Congress, including data on approved medicines such as risankizumab and upadacitinib showing efficacy and safety across several immune-mediated skin diseases. The company also said it would share early results for investigational compounds lutikizumab and zumilokibart.
Key facts and what they mean
Risankizumab and upadacitinib are therapies used to treat conditions like psoriasis, psoriatic arthritis, atopic dermatitis, and related diseases. Real-world and clinical trial data help doctors understand how well these medicines work in broader patient groups and how safe they are when used outside strictly controlled studies. Investigational compounds mentioned indicate ongoing research into new approaches to treat immune-mediated skin diseases.
Who could be affected
People living with alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis, and psoriatic arthritis may be impacted by this research as it could influence treatment options discussed with their healthcare providers. The announcements emphasize diverse patient populations in the studies, suggesting findings aim to apply broadly within dermatology.
Practical next steps
If you or a loved one take a dermatology medicine similar to risankizumab or upadacitinib, continue following your clinician’s guidance and report any side effects. For clinicians, the new abstracts may inform decision-making and discussions about orderings of therapies or consideration of real-world outcomes. Watch for subsequent publications or updates from the EADV Congress for more detailed data and recommendations.
Limits and questions
The source describes conference presentations and early data; it does not provide full study designs, sample sizes, or long-term outcomes in this summary. As with all clinical research, independent evaluation and peer-reviewed publication are needed to confirm findings and to translate them into practice guidelines.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- investingnews.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.